Globus Medical Inc. Class A Common Stock vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Consumer Discretionary Select Sector SPDR Fund trades at $111.11 (market cap $21.99B). The key difference: Consumer Discretionary Select Sector SPDR Fund is far larger — about 2.1× Globus Medical Inc. Class A Common Stock's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Consumer Discretionary Select Sector SPDR Fund for 115 Days on average.
| GMED | XLY | |
|---|---|---|
Market Cap | $10.25B | $21.99B |
Volume | 1,059,528 | 8,302,448 |
Sector | Health | — |
52-Week High | $96.82 | $124.52 |
52-Week Low | $58.33 | $105.64 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $9.76B | — |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
XLY trades at $112.36, showing minimal daily movement with a 0.07% gain. Technical indicators present a mixed picture with a bullish overall signal but bearish moving averages. Analyst consensus is unanimously positive with 100% buy ratings. The ETF has underperformed the consumer staples sector in 2026, declining over 7% while XLP gained 6.6%, creating a significant performance gap according to State Street data as of September 21, 2026.
The consumer discretionary sector faces headwinds from inflation pressures but benefits from resilient consumer spending and 'funflation' trends. Near-term performance will depend on holiday sales momentum and the sector's ability to overcome persistent underperformance versus the broader market. Key risks include inflation impact on consumer wallets and continued sector rotation away from discretionary spending.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →